Hikal Ltd Reports Q4 FY26 Profit of ₹14 Crore Amid Asset Impairment

Revenue: ₹519 crore | Net Profit (PAT): ₹14 crore

Hikal Ltd announced a net profit of ₹14 crore for the fourth quarter of the financial year 2026 (Q4 FY26). This marks a significant turnaround from the ₹6 crore net loss reported in the prior quarter (Q3 FY26). The company's performance this quarter was impacted by an exceptional charge of ₹47 crore related to the impairment of manufacturing assets at its Panoli facility.

Financial Highlights

Hikal Ltd reported revenue of ₹519 crore for Q4 FY26, up from ₹494 crore in Q3 FY26. The company swung to a net profit of ₹14 crore, a notable recovery from the ₹6 crore loss in the previous quarter. This result was achieved despite the ₹47 crore exceptional charge for asset impairment. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the quarter stood at ₹105 crore, with a margin of 20.3%.

The Pharmaceuticals segment generated ₹292 crore in revenue, a sequential decrease from ₹337 crore. However, the company indicated stable performance and progress in overcoming earlier regulatory challenges. The Crop-Protection segment experienced strong sequential growth, with revenue rising to ₹228 crore from ₹157 crore, representing 44% of the total revenue for the quarter.

Significance of the Results

The return to profitability is a positive indicator for investors, suggesting Hikal Ltd is moving past operational difficulties and regulatory issues that affected its Pharmaceuticals division earlier in FY26. The growth in the Crop-Protection segment also provided a substantial revenue boost. Nevertheless, the significant asset impairment charge points to potential challenges in asset valuation or operational efficiency at specific sites, such as the Panoli facility.

In addition to the financial results, the Board of Directors approved a final dividend of 20% of the face value. This brings the total dividend payout for the fiscal year to 30%, offering a return to shareholders.

Background and Operational Context

Hikal Ltd faced regulatory headwinds in its Pharmaceuticals segment during the first half of FY26, which weighed on its performance. The company has been actively engaged in operational improvements. This includes the commissioning of new laboratories and plants in Pune and Panoli, which are now fully operational and are expected to contribute to future growth. The sequential growth across both business segments in the second half of FY26 suggests a recovery trajectory.

Future Outlook and Risks

With new facilities now operational and a recovery evident in the latter half of FY26, Hikal Ltd appears positioned for improved financial results in the upcoming year. Investors will be closely watching for sustained revenue growth and consistent profitability. The company's credit rating from ICRA remains stable at 'A', serving as a positive external assessment.

A primary risk to monitor is the ₹47 crore asset impairment charge, which directly affects reported profits and the company's asset base. Furthermore, the Crop-Protection segment may encounter pricing pressures within the industry, potentially impacting future profit margins despite increases in sales volume.

Key Metrics

• Q4 FY26 Revenue: ₹519 crore (compared to ₹494 crore in Q3 FY26)
• Q4 FY26 Net Profit: ₹14 crore (compared to a ₹6 crore loss in Q3 FY26)
• Exceptional Impairment Charge: ₹47 crore
• EBITDA Margin: 20.3%
• Final Dividend Approved: 20% of face value

Next Steps for Investors

Investors should focus on Hikal Ltd's capacity to maintain revenue momentum, especially in the Pharmaceuticals segment as it navigates its recovery from regulatory challenges. Monitoring the performance of newly commissioned facilities and managing price dynamics in the Crop-Protection business will be critical. Future updates regarding the Panoli facility and overall asset utilization will also be important for assessing the company's operational health.